Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 63Carcinoma, Intraductal, Noninfiltrating 8Breast Carcinoma In Situ 6Neoplasms 4Breast Neoplasms, Male 3Prostatic Neoplasms 2Ovarian Neoplasms 2Infertility 2Endometrial Neoplasms 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Precancerous Conditions 1Polycystic Ovary Syndrome 1Pinealoma 1Pancreatic Neoplasms 1Pancreatic Cyst 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms by Site 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Medulloblastoma 1Inflammatory Breast Neoplasms 1Hypogonadism 1Hyperglycemia 1Hot Flashes 1

Interventions

Letrozole 2trametinib 1ribociclib 1niraparib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × Tamoxifen × 1 year × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡